These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1743921)

  • 41. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of nephrotoxicity between two gadolinium-contrasts, gadodiamide and gadopentetate in patients with mildly diminished renal failure.
    Naito S; Tazaki H; Okamoto T; Takeuchi K; Kan S; Takeuchi Y; Kamata K
    J Toxicol Sci; 2017; 42(3):379-384. PubMed ID: 28496044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experimental study of DOTA-gadolinium. Pharmacokinetics and pharmacologic properties.
    Allard M; Doucet D; Kien P; Bonnemain B; Caillé JM
    Invest Radiol; 1988 Sep; 23 Suppl 1():S271-4. PubMed ID: 3198361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An assessment of Gd-DTPA as a CT contrast agent in the renal tract.
    Gibson RJ; Meanock CI; Torrie EP; Walker TM
    Clin Radiol; 1993 Apr; 47(4):278-9. PubMed ID: 8495577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver].
    Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E
    Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MR contrast enhancement of intracranial lesions with Gd-DTPA.
    Hesselink JR; Press GA
    Radiol Clin North Am; 1988 Jul; 26(4):873-87. PubMed ID: 3289078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The functional effects of gadolinium-DTPA on the isolated perfused rat kidney.
    Brown PW; Haylor JL; Morcos SK; el Nahas AM
    Eur J Radiol; 1993 Feb; 16(2):85-9. PubMed ID: 8462585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA.
    Burtea C; Laurent S; Murariu O; Rattat D; Toubeau G; Verbruggen A; Vansthertem D; Vander Elst L; Muller RN
    Cardiovasc Res; 2008 Apr; 78(1):148-57. PubMed ID: 18174291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cranial MR imaging with Gd-DTPA in neonates and young infants: preliminary experience.
    Elster AD
    Radiology; 1990 Jul; 176(1):225-30. PubMed ID: 2353096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Automated colorimetric gadolinium assay for verification of clearance and estimation of glomerular filtration rate.
    Magnotti RA; Connell JL; Marietta PM
    Clin Chim Acta; 2009 Jan; 399(1-2):59-63. PubMed ID: 18834869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional MR of the kidney.
    Frank JA; Choyke PL; Austin HA; Girton ME
    Magn Reson Med; 1991 Dec; 22(2):319-23. PubMed ID: 1812364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of six radionuclidic and non-radionuclidic methods for the assessment of glomerular filtration rate in patients with chronic renal failure].
    Fotopoulos A; Bokharhli JA; Tsiouris S; Katsaraki A; Papadopoulos A; Tsironi M; Theodorou J
    Hell J Nucl Med; 2006; 9(2):133-40. PubMed ID: 16894423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions.
    Russell EJ; Schaible TF; Dillon W; Drayer B; LiPuma J; Mancuso A; Maravilla K; Goldstein HA
    AJR Am J Roentgenol; 1989 Apr; 152(4):813-23. PubMed ID: 2646872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood-retinal barrier breakdown investigated by real-time magnetic resonance imaging after gadolinium-diethylenetriaminepentaacetic acid injection.
    Berkowitz BA; Sato Y; Wilson CA; de Juan E
    Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):2854-60. PubMed ID: 1917389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver.
    Pavone P; Patrizio G; Buoni C; Tettamanti E; Passariello R; Musu C; Tirone P; Felder E
    Radiology; 1990 Jul; 176(1):61-4. PubMed ID: 2353112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Excretion of gadopentetate dimeglumine in human breast milk.
    Schmiedl U; Maravilla KR; Gerlach R; Dowling CA
    AJR Am J Roentgenol; 1990 Jun; 154(6):1305-6. PubMed ID: 2110745
    [No Abstract]   [Full Text] [Related]  

  • 58. Rate constant of gadolinium (Gd)-DTPA transfer into chronic subdural hematomas.
    Mori K; Mitsuoka H; Cho K; Tajima A; Maeda M
    Neurol Res; 1996 Apr; 18(2):126-34. PubMed ID: 9162866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool and perfusion imaging.
    Schmiedl U; Brasch RC; Ogan MD; Moseley ME
    Acta Radiol Suppl; 1990; 374():99-102. PubMed ID: 1966977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
    Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
    Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.